Merck Sharp + Dohme Corp.

Zhifa Pu

Takao Suzuki

Alexander Pasternak

Jinlong Jiang

Fa-Xiang Ding

Xin Gu

Shuzhi Dong

Joseph P Vacca

Qun Dang

Bin Hu

Ashok Arasappan

Haifeng Tang

Iyassu Sebhat

Philip E Sanderson

Ian W Davies

Richard Soll

Rajan Anand

Jiabing Wang

John J Acton, Iii

Jessica Frie

Qinghong Fu

Mingxiang Cui

Shouning Xu

Reynalda K DeJesus

Hongjie Zhang

Jinfeng Yao

Qi Chen

Shuangxi Hu

Xue Tang

Yongjin Yan

John J Iii Acton

Reynalda K Dejesus

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 

Indole derivatives useful as anti-diabetic agents

The instant invention provides for substituted fused pyrimidine compounds of Formula A that inhibit Akt activity: In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of AKT activity

Growing community of inventors

Shanghai, China

Zhifa Pu